Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies-Reference-Cited by-同舟云学术

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies

Published:2010-10-23 Issue:16 Volume:24 Page:2517-2525
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

McGovern Rachel A,Thielen Alexander,Mo Theresa,Dong Winnie,Woods Conan K,Chapman Douglass,Lewis Marilyn,James Ian,Heera Jayvant,Valdez Hernan,Harrigan P Richard

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference18 articles.

1. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity;Dorr;Antimicrob Agents Chemother,2005

2. Maraviroc for previously treated patients with R5 HIV-1 infection;Gulick;N Engl J Med,2008

3. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection;Cooper;J Infect Dis,2010

4. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211;Wilkin;Clin Infect Dis,2007

5. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211;Gulick;J Infect Dis,2007

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease;Journal of Antimicrobial Chemotherapy;2021-09-16

2. Adapting the geno2pheno[coreceptor] tool to HIV-1 subtype CRF01_AE by phenotypic validation using clinical isolates from South-East Asia;Journal of Clinical Virology;2021-03

3. V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens;Antiviral Chemistry and Chemotherapy;2021-01

4. Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials;PLOS ONE;2018-12-26

5. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc;Journal of Virology;2018-06